<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6</volume><submitter>Chen W</submitter><pubmed_abstract>We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent</pubmed_abstract><journal>Scientific reports</journal><pagination>22976</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4786823</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.</pubmed_title><pmcid>PMC4786823</pmcid><pubmed_authors>Yin X</pubmed_authors><pubmed_authors>Lai J</pubmed_authors><pubmed_authors>Zhang K</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Xiao W</pubmed_authors><pubmed_authors>Liang L</pubmed_authors><pubmed_authors>Chen D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.</name><description>We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Mar</publication><modification>2025-04-18T22:04:00.069Z</modification><creation>2019-03-27T02:10:52Z</creation></dates><accession>S-EPMC4786823</accession><cross_references><pubmed>26964667</pubmed><doi>10.1038/srep22976</doi></cross_references></HashMap>